MDA
MDA Space Ltd
MDA has lower modeled downside risk, despite its lower overall score.
SNDK
Sandisk Corporation
SNDK has the edge over MDA overall, supported by stronger fundamentals and stronger modeled upside.
MDA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Weak | |
| Strong |
MDA's revenue and balance sheet are currently healthy, and its profitability is stable, but its cash flow is weak.
SNDK Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
SNDK's revenue, profitability, cash flow and balance sheet are all currently strong.
MDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 28x | $29.16 | — |
| Cheap | 49x | $27.91 | -4.3% |
| Fair | 51x | $28.95 | -0.7% |
| Current | 51x | $29.16 | — |
| Expensive | 57x | $32.29 | +11% |
Historical ranges are pointers, not guarantees.
MDA has the edge over SNDK in the historical PE scenario, which offers more potential upside but is not a forecast.
SNDK PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 3.8x | $937 | — |
| Current | 7.5x | $937 | — |
| Cheap | 17x | $2,173 | +132% |
| Fair | 24x | $3,048 | +225% |
| Expensive | 59x | $7,452 | +695% |
Historical ranges are pointers, not guarantees.
SNDK's PE is 7.5x, but its earnings don't support one, so it isn't a reliable read right now.
MDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for MDA, but weaker profitability. However, they disagree widely on these estimates.
SNDK Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Moderate | |
| High |
SNDK has the edge over MDA on the outlook, with more favorable profitability expectations.
MDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.05 | +84% |
| Q2 2026 | $0.57 | -14% |
| Q1 2026 | $0.59 | +3.5% |
| Q4 2025 | $0.61 | +30% |
| Q3 2025 | $0.61 | +49% |
| Q2 2025 | $0.66 | +128% |
| Q1 2025 | $0.57 | +104% |
| Q4 2024 | $0.47 | +57% |
| Q3 2024 | $0.41 | +52% |
MDA earned $0.57 per share over the past year, down 14% from the year before.
SNDK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $247.30 | +97% |
| Q3 2026 | $125.61 | +$137.63 |
| Q2 2026 | $73.76 | +$85.07 |
| Q2 2025 | -$11.31 | -$6.65 |
SNDK has the edge over MDA in the latest year-over-year earnings comparison.
MDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $351M | +28% |
| Q1 2026 | $333.7M | +37% |
| Q4 2025 | $363.4M | +51% |
| Q3 2025 | $294.2M | +41% |
| Q2 2025 | $274.2M | +55% |
| Q1 2025 | $243.9M | +58% |
| Q4 2024 | $240.9M | +56% |
| Q3 2024 | $208.7M | +39% |
MDA has the edge over SNDK on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 4.5% | -5.8 points |
| Q1 2026 | 7% | -3.1 points |
| Q4 2025 | 6.4% | +0.3 points |
| Q3 2025 | 3.9% | -5 points |
| Q2 2025 | 10% | +5.7 points |
| Q1 2025 | 10% | +6.7 points |
| Q4 2024 | 6.1% | +5.3 points |
| Q3 2024 | 8.9% | +4 points |
MDA's operating margin was 4.5% last quarter, down 5.8 points from the same quarter a year ago.
SNDK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $11B | +378% |
| Q2 2026 | $9B | +372% |
| Q1 2026 | $6B | +251% |
| Q4 2025 | $3B | +61% |
| Q3 2025 | $2.3B | +23% |
| Q2 2025 | $1.9B | +8% |
| Q1 2025 | $1.7B | -0.6% |
| Q4 2024 | $1.9B | +13% |
SNDK's revenue has grown year over year for six quarters in a row: $11B last quarter, up 378% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 80% | +72 points |
| Q2 2026 | 78% | +78 points |
| Q1 2026 | 69% | +180 points |
| Q4 2025 | 35% | +25 points |
| Q3 2025 | 7.6% | -9 points |
| Q2 2025 | 0.9% | N/A |
| Q1 2025 | -111% | -122 points |
| Q4 2024 | 10% | +6.6 points |
SNDK has the edge over MDA on profitability, with a higher operating margin.
MDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$102.4M | -2464% |
| Q1 2026 | -$4.5M | -102% |
| Q4 2025 | $11.7M | -95% |
| Q3 2025 | -$12.2M | -107% |
| Q2 2025 | $4.3M | -95% |
| Q1 2025 | $205.3M | +$207M |
| Q4 2024 | $230.2M | +$297M |
| Q3 2024 | $164.1M | +$213.5M |
MDA's free cash flow was −$107M over the past year, against $604M the year before.
SNDK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $6.3B | +1340% |
| Q2 2026 | $7.1B | +14355% |
| Q1 2026 | $3B | +$3B |
| Q3 2025 | $438M | +$636M |
| Q2 2025 | $49M | +$217M |
| Q1 2025 | -$18M | +$23M |
| Q3 2024 | -$198M | -$157M |
SNDK has the edge over MDA on cash generation, producing positive trailing cash flow while its opponent burns cash.
MDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7.4% | +9.8M shares |
| 1 year | +11% | +14.5M shares |
| 3 years | +19% | +22.3M shares |
| 5 years | +20% | +23.8M shares |
MDA has 143M diluted shares, up 11% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
MDA hasn't bought back shares in the past year.
SNDK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.6% | -1M shares |
| 1 year | +3.4% | +5M shares |
| 3 years | +6.9% | +10M shares |
SNDK has the edge over MDA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $5B |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
MDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -0.1x | Net Cash |
| Q1 2026 | -0.6x | Net Cash |
| Q4 2025 | 1.0x | Very low |
| Q3 2025 | 0.9x | Very low |
| Q2 2025 | -1.1x | Net Cash |
| Q1 2025 | -1.0x | Net Cash |
| Q4 2024 | -0.2x | Net Cash |
| Q3 2024 | 1.7x | Healthy |
MDA has more cash than debt.
SNDK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.2x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.7x | Net Cash |
SNDK has the edge over MDA on leverage, with a lower net debt burden relative to earnings.
MDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.1 | Neutral |
| Stochastic | 22.8 | Neutral |
MDA's weekly RSI is 46 (neutral) and its Stochastic is 23 (neutral).
SNDK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.2 | Neutral |
| Stochastic | 10.6 | Oversold |
SNDK's weekly RSI is 40 (neutral) and its Stochastic is 11 (oversold).
MDA PE vs Technology Sector
| Metric | MDA | Sector median | Relative |
|---|---|---|---|
| PE | 51x | 28x | 84% above |
| PE % | 58 | 18 | 40 pts above |
MDA is trading at 51x earnings, a 84% premium to the Technology sector's median of 28x, though its earnings don't support one.
SNDK PE vs Technology Sector
| Metric | SNDK | Sector median | Relative |
|---|---|---|---|
| PE | 7.5x | 28x | 73% below |
| PE % | 4 | 27 | 23 pts below |
SNDK has the edge over MDA on valuation relative to its sector.
MDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $28.8 | 1.4% above |
| 20 week MA | $30.7 | 4.9% below |
MDA has stronger trend alignment. MDA is above 1 of 2 weekly averages versus SNDK above 0 of 3.
SNDK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,317.5 | 29% below |
| 20 week MA | $1,465.4 | 36% below |
| 50 week MA | $1,119.6 | 16% below |
SNDK is in a downtrend: it's below all three of its weekly moving averages, and 16% below its 50-week average.
MDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2026 YTD | $29.1 | $29.2 | +0.1% |
It's roughly flat so far in 2026.
SNDK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $50.4 | $250.1 | +396% |
| 2026 YTD | $250.1 | $937.5 | +275% |
SNDK has the edge over MDA on returns for 2026, with the stronger performance.